Non-fatal cardiovascular events

There are 2 papers on non-fatal cardiovascular events in aging research: 1 trial and 1 observational study in people.

Disease

2 papers study it20 more mention it2 findings

5 new papers in 30 daysSee all 22 papers on non-fatal cardiovascular events

“The combination group displayed the lowest risk for developing the composite outcome of non-fatal cardiovascular events after adjusting for age, sex, hypertension, hyperlipidemia, smoking and CAD”
Cardiovascular and economic outcomes of combined liraglutide and empagliflozin therapy in type 2 diabetes: a 6-year studyESC Congress 2026 abstract2026doi:10.1093/eurheartj/ehag785.4186
  • Human trial1
  • Humans1

Interventions

1

Finerenone

downin humans1

1 study
  1. Finerenone decreases non-fatal cardiovascular events in humans (Base-model HRs: low tertile 0.89 (95% CI 0.60–1.32), intermediate 1.11 (0.79–1.56), high 0.85 (0.65–1.11); interaction p=0.57).

    “Finerenone demonstrated consistent CV benefit across AHA PREVENTTM-estimated risk levels.”

    Human trialType 2 diabetes and chronic kidney disease without prior cardiovascular disease; comparison with placebo across baseline PREVENT risk tertilesn = 7,050

    Efficacy of Finerenone in Primary Cardiovascular Prevention: A Mechanistic Analysis Using the AHA PREVENT™ Risk Score

    AHA Scientific Sessions 2026 abstract

More on Finerenone

Associations

1

Liraglutide + empagliflozin

downin humans1HR 4.36

1 study
  1. Liraglutide + empagliflozin is linked with a lower risk of non-fatal cardiovascular events in humans (HR=4.36, 95%CI 2.04-9.33 (insulin vs combination); HR=2.45 for GLP1-RA and HR=3.07 for SGLT2i vs combination).

    “The combination group displayed the lowest risk for developing the composite outcome of non-fatal cardiovascular events after adjusting for age, sex, hypertension, hyperlipidemia, smoking and CAD”

    Humansadjusted for age, sex, hypertension, hyperlipidemia, smoking and CAD; effect shown as insulin vs combination HRmedian follow-up 69 months

    Cardiovascular and economic outcomes of combined liraglutide and empagliflozin therapy in type 2 diabetes: a 6-year study

    ESC Congress 2026 abstract

More on Liraglutide + empagliflozin

Latest

Dec 2025: 1Jan 2026: 1Feb 2026: 0Mar 2026: 1Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 1Sep 2026: 0Oct 2026: 4Nov 2026: 210 papers in 12 months

See all 22 papers on non-fatal cardiovascular events